Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis

NCT04480307 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: temelimab 18 mg/kg
DRUG: temelimab 36 mg/kg
DRUG: temelimab 54 mg/kg
DRUG: Placebo

Sponsor

GeNeuro Innovation SAS